Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Blood (2024) 144 (15): 1595–1610.

https://doi.org/10.1182/blood.2023022884

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood (2024) 143 (6): 496–506.

https://doi.org/10.1182/blood.2023021243

Published: 2024

Includes: Supplemental data

Journal Articles

Skeletal Muscle Index, As a Measure of Muscle Mass, Is a Significant Prognostic Factor for Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma Patients

Blood (2023) 142 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2023-179765

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Loic Ysebaert, Roch Houot, Olivier Casasnovas, Choquet Sylvain, Fabrice Jardin, Michael Loschi, Gabriel Brisou, Catherine Thieblemont, Jacques-Olivier Bay, Cristina Castilla-Llorente, Tom Fradon, Steven Le Gouill, Franck Morschhauser, Guillaume Cartron, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 296.

https://doi.org/10.1182/blood-2023-184653

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Blood (2023) 142 (Supplement 1): 443.

https://doi.org/10.1182/blood-2023-189133

Published: 2023

Journal Articles

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Blood (2023) 142 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2023-185632

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

NARROW

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Skeletal Muscle Index, As a Measure of Muscle Mass, Is a Significant Prognostic Factor for Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma Patients

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only